These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29107277)

  • 21. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
    Elishmereni M; Kheifetz Y; Shukrun I; Bevan GH; Nandy D; McKenzie KM; Kohli M; Agur Z
    Prostate; 2016 Jan; 76(1):48-57. PubMed ID: 26419619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
    Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer.
    Xie W; Drouin S; Nakabayashi M; Pomerantz M; Lee GS; Kantoff PW; Sharifi N
    Prostate; 2016 Oct; 76(14):1338-41. PubMed ID: 27325180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upfront Chemotherapy for Metastatic Prostate Cancer.
    Lam ET; Flaig TW
    Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
    Ceresoli GL; De Vincenzo F; Sauta MG; Bonomi M; Zucali PA
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):374-80. PubMed ID: 26222275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
    Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.
    Lee JL; Eun Kim J; Ahn JH; Lee DH; Lee J; Kim CS; Hyuk Hong J; Hong B; Song C; Ahn H
    Am J Clin Oncol; 2011 Apr; 34(2):140-4. PubMed ID: 20686407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
    Lomax AJ; Parente P; Gilfillan C; Livingston PM; Davis ID; Pezaro C
    Intern Med J; 2016 Feb; 46(2):141-8. PubMed ID: 25732203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?
    Helgstrand JT; Berg KD; Lippert S; Brasso K; Røder MA
    Scand J Urol; 2016 Jun; 50(3):135-43. PubMed ID: 26907159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.